Navigation

Home
Investor Relations
- Corporate Overview
- Officers & Directors
- Management Team
- Stock Quote
- SEC Filings
- Press Releases
- Request Materials
Contact Us

Contact Us

Stellar Pharmaceuticals Inc.
544 Egerton St
London ON, N5W 3Z8
T: 1-800-639-0643
F: 519-434-4382

Press Releases

1 2 >

Release Date	Title (Click to read)
May 15, 2012	Stellar Pharmaceuticals Reports First Quarter 2012 Financial Results
May 14, 2012	Stellar Pharmaceuticals Inc. Secures US$6.0 Million Term Loan to Support Market Growth
Apr 2, 2012	Stellar Pharmaceuticals Strong Product Sales in 2011; Builds for the Future
Mar 29, 2012	Stellar Pharmaceuticals Inc.: Shareholder Early Warning News Release
Mar 21, 2012	Stellar Pharmaceuticals Inc. Announces Correction to Conference Call Access Number Dated March 19, 2012
Mar 19, 2012	Stellar to Hold Conference Call re Health Canada Approval of CAMBIA(R) for the Treatment of Acute Migraines
Mar 16, 2012	Health Canada Approves CAMBIA(R) for the Treatment of Acute Migraine
Jan 26, 2012	Stellar Pharmaceuticals Receives 2nd Uracyst(R) Patent in United States of America
Jan 3, 2012	Stellar Pharmaceuticals Inc.: Conference Call
Jan 3, 2012	Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
Jan 3, 2012	Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
Dec 1, 2011	Stellar to Acquire Tribute Pharmaceuticals to Create Premier North American Specialty Pharmaceutical Company
Nov 14, 2011	Stellar Pharmaceuticals Reports Third Quarter 2011 Financial Results
Sep 13, 2011	Stellar Pharmaceuticals Receives European Approval for NeoVisc(R) Single Dose
Aug 17, 2011	Stellar Pharmaceuticals Issued Uracyst(R) Patent in Japan
Aug 15, 2011	Stellar Pharmaceuticals Reports Second Quarter 2011 Financial Results
Jun 8, 2011	Stellar Pharmaceuticals Engages Advisory Consultant for Its Products in the United States Market
May 16, 2011	Stellar Pharmaceuticals Reports First Quarter 2011 Financial Results
Apr 13, 2011	Stellar Pharmaceuticals Inc. and Watson Pharmaceuticals, Inc. Terminate Uracyst(R) Supply and Licensing Agreements
Mar 31, 2011	Stellar Pharmaceuticals Profitable for 2010; Revenues Up 32% & Net Profit Up 120%

1 2 >